Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01931163
Title NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors The Methodist Hospital System
Indications

triple-receptor negative breast cancer

Therapies

Everolimus

Age Groups: adult
Covered Countries USA


No variant requirements are available.